Magnetic Resonance Spectroscopic Assessment of Isocitrate Dehydrogenase Status in Gliomas: The New Frontiers of Spectrobiopsy in Neurodiagnostics
- 1 January 2020
- journal article
- research article
- Published by Elsevier in World Neurosurgery
- Vol. 133, e421-e427
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- A comparative study of short‐ and long‐TE 1H MRS at 3 T for in vivo detection of 2‐hydroxyglutarate in brain tumorsNMR in Biomedicine, 2013
- 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomasNature Medicine, 2012
- Detection of 2-Hydroxyglutarate in IDH -Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance SpectroscopyScience Translational Medicine, 2012
- Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopyJournal of Neuro-Oncology, 2011
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarateNature, 2009
- IDH1andIDH2Mutations in GliomasNew England Journal of Medicine, 2009
- An Integrated Genomic Analysis of Human Glioblastoma MultiformeScience, 2008
- In vivo quantification of the metabolites in normal brain and brain tumors by proton MR spectroscopy using water as an internal standardMagnetic Resonance Imaging, 2004
- Characterization of lipids from human brain tissues by multinuclear magnetic resonance spectroscopyBiopolymers, 2001
- Estimation of metabolite concentrations from localized in vivo proton NMR spectraMagnetic Resonance in Medicine, 1993